INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (Singapore–January 31, 2021 2:40 p.m. SPT 1:40 a.m. EST)–Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the...